Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | TP53 |
Variant | wild-type |
Impact List | none |
Protein Effect | no effect |
Gene Variant Descriptions | Wild-type TP53 indicates that no mutation has been detected within the TP53 gene. |
Associated Drug Resistance | |
Category Variants Paths |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02143635 | Phase I | Siremadlin | Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt | Completed | USA | FRA | ESP | DEU | 4 |
NCT04116541 | Phase II | Alectinib Cabozantinib Ribociclib + Siremadlin | A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST) | Recruiting | FRA | 0 |
NCT03560882 | Phase I | Atorvastatin | A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies | Recruiting | USA | 0 |
NCT03787602 | Phase Ib/II | Avelumab + KRT-232 KRT-232 | KRT-232 With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma. | Recruiting | USA | ITA | FRA | ESP | DEU | 2 |
NCT03041688 | Phase I | Decitabine + KRT-232 | Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine in Patients With Acute Myeloid Leukemia | Suspended | USA | 0 |
NCT04502394 | Phase Ib/II | Acalabrutinib + KRT-232 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | Recruiting | USA | ITA | FRA | BEL | 7 |
NCT04190550 | Phase I | Cytarabine + Idarubicin + KRT-232 | Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia | Suspended | USA | 0 |
NCT03725436 | Phase I | ALRN-6924 + Paclitaxel | ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors | Recruiting | USA | 0 |
NCT04669067 | Phase Ib/II | KRT-232 + TL-895 | TL-895 and KRT-232 Study in Acute Myeloid Leukemia | Recruiting | USA | ITA | FRA | ESP | DEU | AUT | 2 |
NCT03940352 | Phase I | Siremadlin + Venetoclax Sabatolimab + Siremadlin | HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) | Active, not recruiting | USA | ITA | ESP | DEU | 3 |
NCT01760525 | Phase I | CGM097 | A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors | Completed | USA | FRA | DEU | 2 |
NCT03107780 | Phase I | KRT-232 | Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | Suspended | USA | 0 |
NCT03975387 | Phase Ib/II | ASTX295 | Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 | Recruiting | USA | 0 |
NCT02264613 | Phase Ib/II | ALRN-6924 | Safety Study of ALRN-6924 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01914900 | Phase II | Cisplatin + Docetaxel + Fluorouracil | Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer | Completed | ITA | 0 |
NCT03714958 | Phase I | Siremadlin + Trametinib | Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD) | Recruiting | FRA | 0 |
NCT02909972 | Phase I | ALRN-6924 + Cytarabine ALRN-6924 | Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | Completed | USA | 0 |
NCT04835584 | Phase Ib/II | Dasatinib + KRT-232 KRT-232 + Nilotinib | KRT-232 and TKI Study in Chronic Myeloid Leukemia | Recruiting | USA | ITA | FRA | ESP | CAN | 3 |
NCT02842125 | Phase I | Ad5CMV-p53 gene + Pembrolizumab Ad5CMV-p53 gene + Capecitabine Ad5CMV-p53 gene + Nivolumab | Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer | Terminated | USA | 0 |
NCT03654716 | Phase I | ALRN-6924 + Cytarabine ALRN-6924 | Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer | Recruiting | USA | 0 |
NCT03964233 | Phase I | BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab BI 907828 | A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab) | Recruiting | USA | FRA | ESP | BEL | 6 |
NCT04589845 | Phase II | Alectinib Ado-trastuzumab emtansine Ipatasertib GDC-0077 Entrectinib Atezolizumab Idasanutlin | Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 18 |
NCT03449381 | Phase I | BI 907828 | This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors) | Recruiting | USA | ESP | DEU | CAN | BEL | 2 |
NCT03611868 | Phase Ib/II | APG-115 + Pembrolizumab | A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | Recruiting | USA | 1 |
NCT03654716 | Phase I | ALRN-6924 + Cytarabine ALRN-6924 | Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer | Recruiting | USA | 0 |
NCT03654716 | Phase I | ALRN-6924 + Cytarabine ALRN-6924 | Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer | Recruiting | USA | 0 |
NCT03654716 | Phase I | ALRN-6924 + Cytarabine ALRN-6924 | Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer | Recruiting | USA | 0 |